Results so far suggest that the drug, cabotegravir, was 89 per cent more effective at preventing HIV infection than Truvada pills, although both reduce that risk. The results mirror those announced earlier this year from a similar study testing the shots versus the daily pills in gay men. Cabotegravir is being developed by ViiV Healthcare, which is mostly owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited.The study was sponsored by the US National Institutes of Health, the Bill and Melinda Gates Foundation and ViiV. Read More…
